<?xml version="1.0" encoding="UTF-8"?>
<p id="p0625">Immunosuppression is a well-described risk factor for developing disease following 
 <italic>Leishmania</italic> infection. Coinfection with HIV and VL was first described in Europe but is now recognized in East Africa, Asia, and Brazil. Cases of VL associated with solid organ transplantation have been described. The disease may present atypically in immunosuppressed individuals or be mistaken for a flare of an underlying medical condition [
 <xref rid="bib62" ref-type="bibr">62</xref>]. Europe has also seen an increasing number of leishmaniasis cases in patients treated with TNF inhibitors. One study estimated an eightfold higher risk of opportunistic leishmaniasis in patients treated with monoclonal antibodies compared to controls [
 <xref rid="bib63" ref-type="bibr">63</xref>]. Both VL and CL cases have been described but a relative risk has not been definitively established.
</p>
